Claudio Soto

Active 1994–2025

149
Papers
28,719
Citations
90
h-index
143
i10-index

Citations

Citations per year for Claudio Soto1974: 1 citations1978: 1 citations1984: 1 citations1995: 11 citations1996: 30 citations1997: 52 citations1998: 71 citations1999: 103 citations2000: 130 citations2001: 108 citations2002: 155 citations2003: 140 citations2004: 205 citations2005: 174 citations2006: 260 citations2007: 164 citations2008: 230 citations2009: 233 citations2010: 259 citations2011: 273 citations2012: 260 citations2013: 186 citations2014: 215 citations2015: 182 citations2016: 254 citations2017: 246 citations2018: 236 citations2019: 743 citations2020: 881 citations2021: 953 citations2022: 901 citations2023: 739 citations2024: 1,357 citations2025: 705 citations2026: 18 citations1975–1977: no citations, so these years are not shown1979–1983: no citations, so these years are not shown1985–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,800 citing papers, 24.6% of this breakdownChina: 925 citing papers, 8.1% of this breakdownUnited Kingdom: 765 citing papers, 6.7% of this breakdownItaly: 615 citing papers, 5.4% of this breakdownGermany: 581 citing papers, 5.1% of this breakdownIndia: 496 citing papers, 4.4% of this breakdownSpain: 404 citing papers, 3.5% of this breakdownCanada: 389 citing papers, 3.4% of this breakdownFrance: 340 citing papers, 3% of this breakdownJapan: 329 citing papers, 2.9% of this breakdownAustralia: 292 citing papers, 2.6% of this breakdownSweden: 274 citing papers, 2.4% of this breakdown
0%24.6%Other 27.9%

Fields

  • Medicine53.1%
  • Biochemistry, Genetics and Molecular Biology32%
  • Neuroscience6.9%
  • Materials Science2.8%
  • Agricultural and Biological Sciences0.9%
  • Engineering0.8%
  • Other3.5%

Topics

  • Alzheimer's disease research and treatments13.1%
  • Prion Diseases and Protein Misfolding5.4%
  • Parkinson's Disease Mechanisms and Treatments5.1%
  • Cholinesterase and Neurodegenerative Diseases4.7%
  • Computational Drug Discovery Methods4.3%
  • Neurological diseases and metabolism2.6%
  • Other64.8%

Coauthors

All papers

Open in search
  1. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 693

  2. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Weintraub, Yuge Xiao, Andrew Siderowf, Billy Dunn, Kenneth Marek - The Lancet Neurology 2024 cited by 563

  3. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases

    Authors: , - Nature Neuroscience 2018 cited by 1,155

  4. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy

    Authors: , , , , , , , , , , , , , , - Nature 2020 cited by 876

  5. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid

    Authors: , , , , , , , - JAMA Neurology 2016 cited by 507

  6. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid

    Authors: , , , , - Nature Protocols 2023 cited by 234

  7. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease

    Authors: , , , , , , , , , , , , , , , , , - Acta Neuropathologica Communications 2021 cited by 259

  8. Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort

    Authors: , , , , , , , , , , , , , , - Movement Disorders 2023 cited by 113

  9. Unfolding the role of protein misfolding in neurodegenerative diseases

    Authors: - Nature reviews. Neuroscience 2003 cited by 1,518

  10. Modeling amyloid beta and tau pathology in human cerebral organoids

    Authors: , , , , , - Molecular Psychiatry 2018 cited by 428

  11. Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease

    Authors: , , , , , , , - Movement Disorders 2019 cited by 266

  12. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding

    Authors: , , - Nature 2001 cited by 1,304

  13. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2019 cited by 267

  14. Extensive accumulation of misfolded protein aggregates during natural aging and senescence

    Authors: , , , , , - Frontiers in Aging Neuroscience 2023 cited by 86

  15. Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme

    Authors: , , , , , , , , - Neuron 1996 cited by 1,091

  16. Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease

    Authors: , , , , , , , , , , - Acta Neuropathologica Communications 2022 cited by 75

  17. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease

    Authors: , , , , , , , , , , - Cell Death and Differentiation 2019 cited by 129

  18. Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure

    Authors: , , , , , , , , , , , - Annals of Neurology 2021 cited by 104

  19. Alpha‐Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies

    Authors: , , , , , , , , , , , , - Annals of Neurology 2020 cited by 128

  20. Type 2 diabetes as a protein misfolding disease

    Authors: , , , - Trends in Molecular Medicine 2015 cited by 341

  21. Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding

    Authors: , , , , , - Molecular Psychiatry 2017 cited by 208

  22. Converting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability

    Authors: , - Current Medicinal Chemistry 2002 cited by 598

  23. IRE1 signaling exacerbates Alzheimer’s disease pathogenesis

    Authors: , , , , , , , , , , , , , , - Acta Neuropathologica 2017 cited by 216

  24. Inhibition of protein misfolding and aggregation by natural phenolic compounds

    Authors: , , , , , - Cellular and Molecular Life Sciences 2018 cited by 171